

**CURRICULUM VITAE**  
for  
**Christy A. Schmeck C.M.A**

**CURRENT POSITION:**

Title:	Laboratory Technician/Research Assistant
Institution:	ClinSearch
Address:	6035 Shallowford Rd. Ste. 109 Chattanooga, TN 37421
Telephone:	(423) 698-4584
Fax:	(423) 698-4577
Email:	<a href="mailto:cschmeck@clinsearch-us.com">cschmeck@clinsearch-us.com</a>

**EDUCATION:**

1999-2001	City College Gainesville, FL <ul style="list-style-type: none"><li>• A.S. in Medical Office Administration</li><li>• A.S. in Medical Assisting</li><li>• Graduated Summa Cum Laude</li><li>• Certified First Responder</li></ul>
-----------	---

**PROFESSIONAL EXPERIENCE:**

2009-Present	Laboratory Technician/Research Assistant ClinSearch Chattanooga, TN
2008-2009	Medical Assistant Southeastern Women's Health Gainesville, Florida
2001-2008	Medical Assistant Gainesville Family Physicians Gainesville, FL

## **CONTINUING EDUCATION:**

2009	OSHA
2009	IATA
2009	ORACLE
2009	INFORM
2009	IVRS
2009	MEDIDATA
2009	CITI

## **RESEARCH EXPERIENCE:**

### **REFLUX**

- A DOSE-RESPONSE EFFICACY AND SAFETY STUDY OF ARBACLOFEN PLACARBIL (XP19986) AS ADJUNCTIVE THERAPY IN SUBJECTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD) WHO ARE INCOMPLETE RESPONDERS TO A PROTON PUMP INHIBITOR (PPI)
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER PHASE IIB DOSE FINDING STUDY TO ASSESS THE EFFECT ON GERD SYMPTOMS, SAFETY AND TOLERABILITY DURING FOUR WEEKS TREATMENT WITH AZD3355 IN DOSES 60 MG, 120 MG, 180 MG AND 240 MG BID AS ADD-ON TREATMENT TO A PPI IN PATIENTS WITH GERD THAT ARE PARTIAL RESPONDERS TO PPI TREATMENT

### **GYN**

- A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED, PARALLEL GROUP PROFF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH ENDOMETRIOSIS

- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NBI-56418 NA IN SUBJECTS WITH ENDOMETRIOSIS

### **ENDOCRINOLOGY**

- A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE CONTROLLED PARALLEL GROUP, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ALBIGLUTIDE WHEN USED IN COMBINATION WITH METFORMIN COMPARED WITH METFORMIN PLUS SITAGLIPTIN, METFORMIN PLUS GLIMEPIRIDEM, AND METFORMIN PLUS PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
- A RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND LONG TERM SAFETY OF ALBIGLUTIDE COMPARED WITH INSULIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ALBIGLUTIDE ADMINISTERED IN COMBINATION WITH METFORMIN AND GLIMEPRIDE COMPARED WITH METFORMIN PLUS GLIMEPRIDE AND PLACEBO AND WITH METFORMIN PLUS GLIMEPRIDE AND PIOGLITAZONE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUTOGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ON BACKGROUND TREATMENT WITH GLIMEPRIDE WITH OR WITHOUT METFORMIN
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUTOGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ON BACKGROUND TREATMENT WITH PIOGLITAZONE

### **GASTROENTEROLOGY**

- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL OF LINACLOTIDE ADMINISTERED ORALLY FOR 26 WEEKS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
- AN OPEN-LABEL, LONG-TERM SAFETY STUDY OF ORAL LINACLOTIDE ADMINISTERED TO PATIENTS WITH CHRONIC CONSTIPATION OR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

- A PHASE IIB, DOUBL-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTRE, DOSE-FINDING EFFICACY AND SAFETY STUDY OF RANGE OF DOSES OF A3309 IN PATIENTS IWTH CHRONIC IDIOPATHIC CONSTIPATION
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, DOSE-RESPONSE, STRATIFIED, PLACEBO-CONTROLLED STUDY EVALUATIONG THE SAFETY AND EFFICACY OF SPD476 VERSUS PLACEBO OVER 104 WEEKS IN THE PREVENTION OF RECURRENCE OF DIVERTICULITIS
- GASTROINTESTINAL (GI) RANDOMIZED EVENT AND SAFETY OPEN-LABEL NSAID STUDY (GI REASONS): A RANDOMIZED, OPEN-LABEL, BLINDED-ENDPOINT, PARALLEL-GROUP TRIAL OF GI SAFETY OF CELECOXIB COMPARED WITH NON-SELECTIVE NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS) IN OSTEOARTHRITIS PATIENTS
- A 6-MONTH, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE INCIDENCE OF GASTRIC ULCERS FOLLOWING ADMINISTRATION OF EITHER PA32540 OR ENTERIC COATED ASPRIN 325 MG IN SUBJECTS WHO ARE AT RISK FOR DEVELOPING ASPIRIN-ASSOCIATED ULCERS

### **CARDIOVASCULAR**

- A SIX-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF 300 AND 450 UG/DAY TRANSDERMAL TESTOSTERONE IN FEMAL PATIENTS WITH LOW EJECTION FRACTION AND SYMPTOMIC HEART FAILURE
- A PHASE 3, OPEN-LABEL, RANDOMIZED, LONG-TERM COMPARISON OF THE SAFETY AND TOLERABILITY OF THE TAK-491 PLUS CHLORTHALIDONE FIXED-DOSE COMBINATION VS. OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE FIXED-DOSE COMBINATION IN SUBJECTS WITH ESSENTIAL HYPERTENSION

### **MIGRAINE**

- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF MAP0004 IN ADULT MIGRAINUEURS FOR A SINGLE MIGRAINE FOLLOWED BY OPEN LABEL EXTENSIONS TO 26/52 WEEKS

---

Signature